and G.H.K.; financing acquisition, K.W.K.; analysis, H.J.P., G.H.K., C.W.L., and S.Con.; technique, H.J.P., G.H.K., and K.W.K.; task administration, K.W.K.; assets, H.J.P. influence of iRECIST on evaluating treatment efficiency of immune
ROCK inhibitors
and G.H.K.; financing acquisition, K.W.K.; analysis, H.J.P., G.H.K., C.W.L., and S.Con.; technique, H.J.P., G.H.K., and K.W.K.; task administration, K.W.K.; assets, H.J.P. influence of iRECIST on evaluating treatment efficiency of immune